DEALS
Zhong Lun Assists Lianhe Investment to Lead Investment in Series A + Financing of WillingMed
Zhong Lun Assists Lianhe Investment to Lead Investment in Series A + Financing of WillingMed
WillingMed Technology (Beijing) Co., Ltd. (“WillingMed"), a clinical infection pathogenic microorganism detection service provider, recently announced that it had successfully completed its Series A+ financing of hundreds of millions in RMB, an investment led exclusively by Shanghai Lianhe Investment Co., Ltd. (“Lianhe Investment")
Acting as legal counsel for Lianhe Investment, Zhong Lun rendered services including legal due diligence, review and drafting of transaction documents and legal advice on related legal issues. Zhong Lun team was led by partner Steve Zhao and supported by associates Xihan Zhou, Mengyang Jin, etc.
Lianhe Investment is a state-owned investment company established with the approval of the Shanghai municipal government in 1994. With a mission of contributing to the implementation of national strategies and promoting the development of science and innovation, the company is committed to developing key technologies and making breakthroughs in technological cul-de-sacs, with a strong focus on information technology, life and health, energy and intelligent manufacturing, etc. The scale of its investment has exceeded RMB 10 billion.
WillingMed is a high-tech company focusing on precision diagnosis of infectious diseases and individualized medicine. It has a number of core technologies in mNGS and microfluidic automated chips and is actively filing a dozen of mNGS IVD pipeline products covering reagents, devices, software and other applications, with several products already registered. WillingMed is one of the few companies in the industry that can provide a whole process automation solution for mNGS.